Thymosin alpha-1 reversed the immunosuppressive side effects of oncolytic adenoviruses by reprogramming tumor-associated macrophages from a tumor-promoting to a tumor-fighting state, significantly enhancing anti-cancer immunity.
M2 to antitumoral reprogrammingThymosin alpha-1 converted immunosuppressive M2 macrophages to a cancer-fighting phenotype, overcoming the key limitation of oncolytic adenovirus therapy and enhancing tumor killing through CD8+ T cells.
What the researchers found
Type V adenovirus (ADV) was shown to induce tumor-associated macrophage (TAM) polarization to the immunosuppressive M2 phenotype and increase regulatory T cell (Treg) infiltration in the tumor microenvironment — an immunosuppressive feedback loop that counteracts the virus's anti-cancer effects.
Thymosin alpha-1 selectively compensated for these deficiencies by reprogramming M2-like TAMs toward an antitumoral phenotype and reshaping the tumor microenvironment for improved anti-tumor immunity. An engineered adenovirus (ADVTα1) that produces Tα1 directly enhanced anti-tumor efficacy through CD8+ T cell activation, demonstrating that both externally supplied and virus-produced Tα1 effectively orchestrate macrophage reprogramming.
Why it matters
Oncolytic virus therapy is one of the most promising frontiers in cancer treatment, but its effectiveness has been limited. This study identifies a specific reason why — the virus inadvertently creates immune suppression — and provides a peptide-based solution. By combining oncolytic viruses with thymosin alpha-1, researchers could potentially overcome a major barrier to effective virus-based cancer immunotherapy.
How the study worked
Researchers first characterized the immunosuppressive effects of type V adenovirus on the tumor microenvironment, examining macrophage polarization and Treg infiltration. They then tested thymosin alpha-1 both as an exogenous supplement and as a gene engineered into the adenovirus (ADVTα1). Anti-tumor efficacy was evaluated in mouse cancer models, with immune profiling of the tumor microenvironment including TAM phenotyping and CD8+ T cell analysis.
What this study cannot tell us
This is a preclinical study in mouse models, and mouse tumor microenvironments differ from human cancers. The specific adenovirus serotype (type V) may have different immunomodulatory effects than other oncolytic viruses. Long-term safety of engineered ADVTα1 was not assessed. Clinical translation would require extensive safety testing given the combination of a replicating virus with an immunomodulatory peptide.
How to read the evidence
Published in Cell Reports Medicine (a high-impact journal), this is a rigorous preclinical study with mechanistic depth. However, all findings are from mouse models, and clinical translation remains to be demonstrated.
When this study was published
Published in 2024, this is very recent research addressing a current challenge in the rapidly evolving field of oncolytic virotherapy and cancer immunotherapy.
The bigger picture
This study sits at the intersection of two important fields: oncolytic virotherapy and peptide immunomodulation. It reveals that even promising cancer therapies can trigger counter-regulatory immune responses that limit their effectiveness. The approach of engineering the therapeutic virus to co-deliver an immune-correcting peptide represents an elegant strategy that could be applied to other combination immunotherapies facing similar immunosuppressive feedback challenges.
Questions still open
- Would thymosin alpha-1 combination improve the efficacy of other oncolytic viruses beyond adenovirus type V?
- Could this ADVTα1 approach be effective against tumor types that are particularly resistant to immunotherapy due to highly immunosuppressive microenvironments?
- What is the optimal dosing of thymosin alpha-1 relative to viral load to maximize immune reprogramming without causing autoimmune-like effects?
Common questions
What is thymosin alpha-1 and how does it help fight cancer?
Why do oncolytic viruses sometimes make the tumor immune environment worse?
Read the original research
Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy.
Cell reports. Medicine, 5(10), 101751
Citation
Liu, Kua; Kong, Lingkai; Cui, Huawei; Zhang, Louqian; Xin, Qilei; Zhuang, Yan; Guo, Ciliang; Yao, Yongzhong; Tao, Jinqiu; Gu, Xiaosong; Jiang, Chunping; Wu, Junhua. (2024). Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy.. Cell reports. Medicine, 5(10), 101751. https://doi.org/10.1016/j.xcrm.2024.101751